Paradox-Breaking RAF Inhibitors That Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma

(Cancer Cell 27, 85–96, January 12, 2015) The authors have noted an error in Figure 6A of the originally published version of this article. The image for pERK (top right panel) was incorrectly duplicated from Figure 4E (top right panel). The corrected Figure 6 is shown here. This error does not alter the original conclusions of the study, but the authors wish to apologize for this oversight and any confusion that may have resulted. Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant MelanomaGirotti et al.Cancer CellDecember 11, 2014In BriefGirotti et al. describe two pan-RAF inhibitors that also inhibit SRC-family kinases. These compounds do not drive paradoxical MEK/ERK activation and can inhibit MEK in NRAS mutant cells. Moreover, the agents can overcome resistance to clinical BRAF or combination BRAF/MEK inhibitors in patient-derived xenografts. Full-Text PDF Open Access